IS2057B - Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti - Google Patents

Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti

Info

Publication number
IS2057B
IS2057B IS5032A IS5032A IS2057B IS 2057 B IS2057 B IS 2057B IS 5032 A IS5032 A IS 5032A IS 5032 A IS5032 A IS 5032A IS 2057 B IS2057 B IS 2057B
Authority
IS
Iceland
Prior art keywords
fkbp12
stimulate
association
sensitive
compounds
Prior art date
Application number
IS5032A
Other languages
English (en)
Other versions
IS5032A (is
Inventor
E. Zelle Robert
Su Michael
Original Assignee
Vertex Pharmaceuticals Incorporated.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25009484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2057(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated. filed Critical Vertex Pharmaceuticals Incorporated.
Publication of IS5032A publication Critical patent/IS5032A/is
Publication of IS2057B publication Critical patent/IS2057B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS5032A 1996-11-13 1999-04-21 Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti IS2057B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/748,447 US5840736A (en) 1996-11-13 1996-11-13 Methods and compositions for stimulating neurite growth
PCT/US1997/020866 WO1998020891A1 (en) 1996-11-13 1997-11-13 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors

Publications (2)

Publication Number Publication Date
IS5032A IS5032A (is) 1999-04-21
IS2057B true IS2057B (is) 2005-10-14

Family

ID=25009484

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5032A IS2057B (is) 1996-11-13 1999-04-21 Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti

Country Status (33)

Country Link
US (3) US5840736A (is)
EP (1) EP0946190B1 (is)
JP (1) JP2001504470A (is)
KR (1) KR100544451B1 (is)
CN (1) CN1168442C (is)
AP (1) AP9901518A0 (is)
AR (1) AR011278A1 (is)
AT (1) ATE250424T1 (is)
AU (1) AU724833B2 (is)
BG (1) BG64670B1 (is)
BR (1) BR9712765A (is)
CA (1) CA2270634A1 (is)
CO (1) CO4930260A1 (is)
CZ (1) CZ296058B6 (is)
DE (1) DE69725169T2 (is)
DK (1) DK0946190T3 (is)
EA (1) EA004247B1 (is)
ES (1) ES2206753T3 (is)
HK (1) HK1022851A1 (is)
HU (1) HU226728B1 (is)
IL (1) IL129555A (is)
IN (1) IN183740B (is)
IS (1) IS2057B (is)
NO (1) NO328030B1 (is)
NZ (1) NZ335394A (is)
PL (1) PL190903B1 (is)
PT (1) PT946190E (is)
SK (1) SK284535B6 (is)
TR (1) TR199901034T2 (is)
TW (1) TW513302B (is)
UA (1) UA63926C2 (is)
WO (1) WO1998020891A1 (is)
ZA (1) ZA9710256B (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999062880A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
KR20010071920A (ko) 1998-07-17 2001-07-31 개리 이. 프라이드만 뉴우런 성장 및 연장을 자극하는 화합물, 조성물 및 방법
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6228872B1 (en) * 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
EP1135105B1 (en) * 1998-12-09 2005-03-02 Chiron Corporation Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
JP2002534414A (ja) * 1999-01-08 2002-10-15 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬の製造に有用な中間体の形成方法
WO2001002368A1 (en) 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-heterocyclic derivatives with neuronal activity
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AU6497200A (en) * 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
ES2269206T3 (es) * 1999-11-12 2007-04-01 Alcon, Inc. Ligandos de neurofilina para tratar trastornos oculares.
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
ATE319712T1 (de) 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
AU2002259305A1 (en) * 2001-05-25 2002-12-09 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
EP1404325A2 (en) * 2001-05-29 2004-04-07 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
CN101605556A (zh) * 2006-12-20 2009-12-16 瑞纳神经科学公司 治疗自体免疫疾病的trkb激动剂
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
WO2019222339A1 (en) 2018-05-15 2019-11-21 Tran Lloyd Hung Loi Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
WO2014051091A1 (ja) * 2012-09-28 2014-04-03 Dic株式会社 α－アルミナ微粒子及びその製造方法

Also Published As

Publication number Publication date
NO992138D0 (no) 1999-05-03
IN183740B (is) 2000-04-01
CA2270634A1 (en) 1998-05-22
EP0946190B1 (en) 2003-09-24
CN1239433A (zh) 1999-12-22
AU724833B2 (en) 2000-09-28
US5840736A (en) 1998-11-24
NO992138L (no) 1999-07-13
CZ296058B6 (cs) 2006-01-11
PL333270A1 (en) 1999-11-22
NZ335394A (en) 2000-06-23
IS5032A (is) 1999-04-21
EP0946190A1 (en) 1999-10-06
TW513302B (en) 2002-12-11
HUP0001219A3 (en) 2001-12-28
NO328030B1 (no) 2009-11-16
HK1022851A1 (en) 2000-08-25
HUP0001219A2 (hu) 2000-11-28
BG64670B1 (bg) 2005-11-30
HU226728B1 (en) 2009-08-28
KR100544451B1 (ko) 2006-01-24
SK62899A3 (en) 2000-04-10
DE69725169T2 (de) 2004-07-15
PL190903B1 (pl) 2006-02-28
TR199901034T2 (xx) 1999-07-21
EA199900464A1 (ru) 2000-02-28
CO4930260A1 (es) 2000-06-27
PT946190E (pt) 2004-02-27
SK284535B6 (sk) 2005-06-02
AP9901518A0 (en) 1999-06-30
DE69725169D1 (de) 2003-10-30
AR011278A1 (es) 2000-08-16
BR9712765A (pt) 1999-10-26
AU5258998A (en) 1998-06-03
EA004247B1 (ru) 2004-02-26
US6172086B1 (en) 2001-01-09
US6284778B1 (en) 2001-09-04
ZA9710256B (en) 1998-05-28
WO1998020891A1 (en) 1998-05-22
IL129555A (en) 2005-08-31
JP2001504470A (ja) 2001-04-03
CN1168442C (zh) 2004-09-29
KR20000068962A (ko) 2000-11-25
CZ168399A3 (cs) 1999-08-11
ATE250424T1 (de) 2003-10-15
ES2206753T3 (es) 2004-05-16
DK0946190T3 (da) 2003-12-08
BG103429A (en) 2000-04-28
IL129555A0 (en) 2000-02-29
UA63926C2 (uk) 2004-02-16

Similar Documents

Publication Publication Date Title
IS2057B (is) Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti
NO20006604D0 (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
NO994506D0 (no) FremgangsmÕter og blandinger for Õ modulere mottagelighet for kortikosteroider
DE19782118T1 (de) Photovoltaische Vorrichtung und ihr Vorbereitungsverfahren
NO942193D0 (no) Metallocener og fremgangsmåte til deres fremstilling og bruk
IS4731A (is) Kínólín og kínazólín efnasambönd nytsamleg í meðferð
NO900281D0 (no) Fremgangsmaate for broennstimulering i oljeproduksjonsprosessen og anordning for aa utfoere fremgangsmaaten.
DE69734300D1 (de) Vorrichtung zum Aufbewahren und Auftragen
ID20400A (id) Komposisi dan metoda untuk menghambat penuaan akibat cahaya pada kulit
DE69413930D1 (de) Hilfsmittel zur Verringerung der Fleckenbildung in photothermographischen und thermographischen Elementen
DE69728057D1 (de) Iontophoretische auslösbare lieferungsvorrichtung zur verminderung von elektrischen empfindungen
DE69502201D1 (de) Übergossenes zusatzteil zur zugentlastung und zum verhindern von verhakung
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
AT397676B (de) Vorrichtung zum sichern von böschungen und hängen
DE69708738D1 (de) Vorrichtung zum Ausgleich von Momentschwankungen
DE69828345D1 (de) Kreuzkorrelationsverfahren und Vorrichtung zur Unterdrückung der Effekte von Mehrfachstreuung
IS4628A (is) Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka
NO984836L (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
DE69712502D1 (de) Vorrichtung zur stimulation der herzfunktion
GB2286613B (en) Improvements in or relating to methods and apparatus for improving the condition of ground
DK521489A (da) Desacetoxycephalosporin c synthase i oprenset form og fremgangsmaade til fremstilling af dette enzym
NO980396D0 (no) Börste med forbedret bustknipperetensjon og forankringsstreng for dette
DE68929258D1 (de) Mikrorechner und Prüfverfahren
ATA106488A (de) Einrichtung zum ableiten von regenwasser u.dgl.
FI103056B1 (fi) Menetelmä ja testipakkaus näytteenottopinnan esikäsittelemiseksi